Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Differentiating brown tumor due to primary hyperparathyroidism from a giant cell tumor remains a clinical challenge. Misdiagnosis may lead to inappropriate oncologic treatment and unnecessary surgical interventions.

Case Presentation: We report the case of a 52-year-old Caucasian white woman of Albanian ethnicity with multiple osteolytic bone lesions and a history of repeated orthopedic surgeries over 5 years. Initial histopathology suggested aneurysmal bone cyst and giant cell tumor, while imaging findings were interpreted as metastatic bone disease, and led to chemotherapy and radiotherapy in the absence of a confirmed primary malignancy. The patient was later referred to our Nuclear Medicine Unit, where a repeat bone scintigraphy indicated metabolic bone disease. A full biochemical evaluation revealed severe hypercalcemia and elevated parathyroid hormone. Parathyroid scintigraphy confirmed a hyperfunctioning parathyroid adenoma. Retrospective review of previous pathology reports supported the diagnosis of brown tumor. The patient underwent successful parathyroidectomy. Biochemical parameters normalized within 3 months postoperatively, and no complications such as hypocalcemia were observed.

Conclusion: This case illustrates the importance of early consideration of primary hyperparathyroidism in the differential diagnosis of multifocal lytic bone lesions. Accurate diagnosis requires a multidisciplinary approach combining imaging, histopathology, and biochemical evaluation to prevent misdiagnosis and overtreatment.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12392585PMC
http://dx.doi.org/10.1186/s13256-025-05509-3DOI Listing

Publication Analysis

Top Keywords

brown tumor
12
giant cell
12
cell tumor
12
primary hyperparathyroidism
12
tumor primary
8
bone lesions
8
bone disease
8
biochemical evaluation
8
bone
6
tumor
5

Similar Publications

Hibernomas are infrequent brown adipose tissue tumors that can mimic various other soft tissue tumors, both malignant and benign, and multiple imaging modalities are usually used in the diagnostic approach. We present the case of a 30-year-old female patient who was initially diagnosed with a mediastinal hibernoma through complete excisional biopsy in 2022 and underwent surgical resection at that time. She required a second surgical intervention in 2024 due to recurrence and is now being evaluated for a second recurrence using fluorine-18 fluorodeoxyglucose positron-emission tomography/computed tomography (18F-FDG PET/CT), reporting an extensive polylobulated mediastinal tumor intercalating normometabolic and discretely hypermetabolic zones.

View Article and Find Full Text PDF

Enigmatic Roles of Complement Anaphylatoxin Signaling in Health and Disease.

Immune Netw

August 2025

Center for Metabolic and Degenerative Diseases, The Brown Foundation Institute of Molecular Medicine for Prevention of Human Diseases, UTHealth-McGovern Medical School, Houston, TX 77030, USA.

Complement anaphylatoxins C3a and C5a are potent immunomodulators whose impact extends well beyond their traditional roles in innate immunity. Acting through G protein-coupled receptors C3aR, C5aR1, and C5aR2, these peptides take part in coordinating immune cell recruitment, vascular tone, and tissue remodeling. Yet their functions are deeply context-dependent: while they play essential roles in microbial clearance and immune coordination, their overactivation contributes to immunopathology in a wide range of diseases.

View Article and Find Full Text PDF

Background: Non-small-cell lung cancer NSCLC is the major diagnosed type of lung cancers in the USA and Europe. It is generally related to poor prognosis and low rates of survival. Oleandrin is a cardiac glycoside occurring naturally in Nerium oleander (Apocynaceae).

View Article and Find Full Text PDF

Remodeling the sarcoma microenvironment by simultaneous targeting of urokinase-type plasminogen activator receptors and epidermal growth factor receptors to promote antitumor activity.

J Pharmacol Exp Ther

August 2025

Animal Cancer Care and Research Program, University of Minnesota, St Paul, Minnesota; Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St Paul, Minnesota; Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota; Center for Immunology

We evaluated the antitumor effects of remodeling the MC17 mouse sarcoma microenvironment (SME) by targeting urokinase-type plasminogen activator receptor (uPAR)- and epidermal growth factor receptor (EGFR)-expressing cells. Specifically, we used eBAT (a bispecific ligand-targeted toxin directed to EGFR and uPAR), and its mouse counterpart, meBAT, to ablate uPAR- and/or EGFR-expressing cells. We chose the MC17 model because the cells are resistant to eBAT, allowing us to exclusively evaluate the role of uPAR- and EGFR-expressing cells in the SME.

View Article and Find Full Text PDF

Background: Cancer morbidity disproportionately affects patients in low- and middle-income countries (LMICs), where timely and accurate tumor profiling is often nonexistent. Immunohistochemistry-based assessment of estrogen receptor (ER) status, a critical step to guide use of endocrine therapy (ET) in breast cancer, is often delayed or unavailable. As a result, ET is often prescribed empirically, leading to ineffective and toxic treatment for ER-negative patients.

View Article and Find Full Text PDF